The Technical AnalystExchange: PNK Industry: Biotechnology
Mymetics Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% €0.0100
America/New_York / 16 feb 2024 @ 12:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.04 mill |
| EPS: | -111.08 |
| P/E: | 0 |
| Earnings Date: | May 15, 2023 |
| SharesOutstanding: | 303.76 mill |
| Avg Daily Volume: | 0.0000 mill |
| RATING 2024-02-16 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ -0.116 - 0.136 ( +/- 1 260.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2015-04-09 | Kempers Ronald Hugo Gerard | Buy | 5 000 000 | Stock options |
| 2006-01-31 | Round Enterprises, Ltd. | Sell | 0 | Common Stock |
| 2006-01-31 | Round Enterprises, Ltd. | Sell | 0 | Convertible Notes |
| 2013-10-04 | Fleury Sylvain | Buy | 800 000 | Stock Options |
| 2009-12-31 | Fleury Sylvain | Buy | 350 000 | Stock Options |
| INSIDER POWER |
|---|
| 0.00 |
| Last 30 transactions |
| Buy: 27 300 000 | Sell: 9 617 276 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.0100 (0.00% ) |
| Volume | 0.0000 mill |
| Avg. Vol. | 0.0000 mill |
| % of Avg. Vol | 383.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MYMX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MYMX
Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.